Skip to main content

Function

Plays a key role in both adaptive and innate immune signaling by bridging CARD domain-containing proteins to immune activation (PubMed:10187770, PubMed:10364242, PubMed:10400625, PubMed:24074955, PubMed:25365219). Acts by channeling adaptive and innate immune signaling downstream of CARD domain-containing proteins CARD9, CARD11 and CARD14 to activate NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines (PubMed:24074955). Recruited by activated CARD domain-containing proteins: homooligomerized CARD domain-containing proteins form a nucleating helical template that recruits BCL10 via CARD-CARD interaction, thereby promoting polymerization of BCL10, subsequent recruitment of MALT1 and formation of a CBM complex (PubMed:24074955). This leads to activation of NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines (PubMed:18287044, PubMed:24074955, PubMed:27777308). Activated by CARD9 downstream of C-type lectin receptors; CARD9-mediated signals are essential for antifungal immunity (PubMed:26488816). Activated by CARD11 downstream of T-cell receptor (TCR) and B-cell receptor (BCR) (PubMed:18264101, PubMed:18287044, PubMed:24074955, PubMed:27777308). Promotes apoptosis, pro-caspase-9 maturation and activation of NF-kappa-B via NIK and IKK (PubMed:10187815).

Involvement in disease

A chromosomal aberration involving BCL10 is recurrent in low-grade mucosa-associated lymphoid tissue (MALT lymphoma). Translocation t(1;14)(p22;q32). Although the BCL10/IgH translocation leaves the coding region of BCL10 intact, frequent BCL10 mutations could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions.

Immunodeficiency 37

IMD37

A form of primary combined immunodeficiency, a group of disorders characterized by severe recurrent infections, with normal numbers or an absence of T and B lymphocytes, and impaired cellular and humoral immunity. IMD37 is characterized by hypogammaglobulinemia without lymphopenia, but with profoundly reduced memory B cells and memory T cells, and increased numbers of circulating naive lymphocytes. Inheritance is autosomal recessive.

None

The disease is caused by variants affecting the gene represented in this entry.

Lymphoma, mucosa-associated lymphoid type

MALTOMA

A subtype of non-Hodgkin lymphoma, originating in mucosa-associated lymphoid tissue. MALT lymphomas occur most commonly in the gastro-intestinal tract but have been described in a variety of extranodal sites including the ocular adnexa, salivary gland, thyroid, lung, thymus, and breast. Histologically, they are characterized by an infiltrate of small to medium-sized lymphocytes with abundant cytoplasm and irregularly shaped nuclei. Scattered transformed blasts (large cells) also are present. Non-malignant reactive follicles are observed frequently. A pivotal feature is the presence of lymphoepithelial lesions, with invasion and partial destruction of mucosal glands and crypts by aggregates of tumor cells.

None

The disease is caused by variants affecting the gene represented in this entry.

Post-translational modifications

Phosphorylated. Phosphorylation results in dissociation from TRAF2 and binding to BIRC2/c-IAP2 (PubMed:11466612). Phosphorylated by IKBKB/IKKB (PubMed:17213322).

Ubiquitinated via both 'Lys-63'-linked and linear ('Met-1'-linked) polyubiquitin chains in response to T-cell receptor (TCR) activation (PubMed:18287044, PubMed:27777308). Ubiquitination is recognized by IKBKG/NEMO, the regulatory subunit of I-kappa-B kinase (IKK), and is required for TCR-induced NF-kappa-B activation (PubMed:18287044, PubMed:27777308). Linear ubiquitination at Lys-17, Lys-31 and Lys-63 is mediated by RNF31/HOIP; linear ubiquitination is recognized with much higher affinity than 'Lys-63'-linked ubiquitin by IKBKG/NEMO (PubMed:27777308). CARD11 is required for linear ubiquitination by HOIP by promoting the targeting of BCL10 to RNF31/HOIP (PubMed:27777308).

Proteolytically cleaved by MALT1; required for T-cell activation.

Tissue specificity

Ubiquitous.

Cellular localization

  • Cytoplasm
  • Perinuclear region
  • Membrane raft
  • Appears to have a perinuclear, compact and filamentous pattern of expression. Also found in the nucleus of several types of tumor cells. Colocalized with DPP4 in membrane rafts.

Alternative names

CIPER, CLAP, BCL10, B-cell lymphoma/leukemia 10, B-cell CLL/lymphoma 10, CARD-containing molecule enhancing NF-kappa-B, CARD-like apoptotic protein, CED-3/ICH-1 prodomain homologous E10-like regulator, Cellular homolog of vCARMEN, Cellular-E10, Mammalian CARD-containing adapter molecule E10, Bcl-10, hCLAP, cCARMEN, c-E10, mE10

Target type

Proteins

Primary research area

Immuno-oncology

Molecular weight

26252Da

We found 27 products in 3 categories

Proteins & Peptides

Target

Species of origin

Cell Lines & Lysates

Target

Cell type

Species or organism

Search our catalogue for 'BCL10' (27)

Products

ab33905

Anti-Bcl10 antibody [EP606Y]

Recombinant
RabMAb
KO Validated

ab150380

Anti-Bcl10 antibody [EPR8587]

Recombinant
RabMAb
KO Validated

ab40752

Anti-Bcl10 antibody [ep605y]

Recombinant
RabMAb

ab108328

Anti-Bcl10 antibody [EPR3175]

Recombinant
RabMAb

ab108412

Anti-Bcl10 antibody [EPR3174]

Recombinant
RabMAb

ab189219

Anti-Bcl10 antibody [EP606Y] - BSA and Azide free

Recombinant
RabMAb
KO Validated

ab248953

Anti-Bcl10 antibody [EPR8587] - BSA and Azide free

Recombinant
RabMAb
KO Validated

ab261797

Human BCL10 knockout HeLa cell line

Advanced Validation

ab305689

PE Anti-Bcl10 antibody [EP606Y]

Recombinant
RabMAb